Developing Next-Generation Treatments
for Herpes Simplex-Induced Diseases

Read more

About us

With its clinical and medical experts, the team of Innovative Molecules dedicates its work to patients suffering from herpes mediated diseases.

Pipeline

IM-250 is a novel, orally available, selective HSV-helicase primase inhibitor. Helicase primase inhibitors block unwinding of DNA in the ...

News

Latest News, Media, Press Releases and Updates

News & Press

03 September 2025

Publication in Antiviral Research: Structural determinants of nervous system exposure of adibelivir (IM-250) and related herpes helicase-primase inhibitors across animal species

Read More +

27 October 2023

Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV

Read More +

15 June 2023

Innovative Molecules Announces First Subjects Dosed in the German Phase 1 Clinical Trial of IM-250

Read More +

16 June 2021

Science Translational Medicine Publication: Innovative Molecules ́ Drug Candidate Affects Recurrent Herpes Simplex Virus Infections

Read More +

07 June 2021

Innovative Molecules raises €20 million Series A equity financing round

Read More +

View all